{"title": "Types of COVID-19 Vaccines", "author": null, "url": "https://www.sutterhealth.org/for-patients/health-alerts/covid-19-vaccine-types", "hostname": "sutterhealth.org", "description": "Vaccination is the best defense against COVID-19. Learn more about the coronavirus vaccines currently available from Pfizer-BioNTech, Moderna and Janssen/J&J.", "sitename": "sutterhealth.org", "date": "2023-05-17", "cleaned_text": "Different COVID-19 Vaccines |Topic||Pfizer*||Moderna||Janssen/J&J||NOVAVAX| |Emergency use in the U.S.|| |[Yes, for ages 6 months+ with full FDA approval for ages 18+](https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/moderna-covid-19-vaccines) [Yes, for ages 18+](https://www.fda.gov/media/146305/download) [Yes, for ages 12+](https://www.fda.gov/media/146305/download) 6 months - 4 years: 3 bivalent doses (3-8 weeks between dose 1 and 2, at least 8 weeks between dose 2 and 3) 5 years and older: 1 bivalent dose 6 months - 5 years: 2 bivalent doses 4 - 8 weeks apart 6 years and older: 1 bivalent dose 18+ years: 1 shot [mRNA](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html) [mRNA](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html) [Viral vector](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html) [Adjuvanted](https://www.niaid.nih.gov/research/vaccine-adjuvants) If viewing this chart on your phone, scroll to the left to see all vaccines. *See schedule for COVID-19 vaccination for [ people who are moderately or severely immunocompromised.](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#vaccination-people-immunocompromised) ** [According to the CDC](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series), an 8-week interval between the first and second primary series doses of Moderna, Novavax and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months-64 years, especially for males age 12-39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines. ***A monovalent Novavax booster dose (instead of a bivalent mRNA vaccine) may be used in limited situations in people ages 18 years and older who completed a primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster "}